Show simple item record

dc.contributor.authorXiridou, Maria
dc.contributor.authorVisser, Maartje
dc.contributor.authorUrbanus, Anouk
dc.contributor.authorMatser, Amy
dc.contributor.authorvan Benthem, Birgit
dc.contributor.authorVeldhuijzen, Irene
dc.date.accessioned2021-05-05T18:44:26Z
dc.date.available2021-05-05T18:44:26Z
dc.date.issued2021-04-22
dc.identifier.pmid33896665
dc.identifier.doi10.1016/j.vaccine.2021.04.008
dc.identifier.urihttp://hdl.handle.net/10029/624927
dc.language.isoenen_US
dc.rightsCopyright © 2021 Elsevier Ltd. All rights reserved.
dc.subjectHepatitis B virusen_US
dc.subjectMathematical modelen_US
dc.subjectMen who have sex with menen_US
dc.subjectRisk-group vaccinationen_US
dc.subjectUniversal vaccinationen_US
dc.subjectVaccinationen_US
dc.titleEnding risk-group HBV vaccination for MSM after the introduction of universal infant HBV vaccination: A mathematical modelling study.en_US
dc.typeArticleen_US
dc.identifier.eissn1873-2518
dc.identifier.journalVaccine 2021; 39(21):2867-75en_US
dc.source.journaltitleVaccine
dc.source.countryNetherlands


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record